Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Patient visits complete in Alzheimer’s Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

LabNews Media LLC

Os Editores Principais da labnews.ai são Marita Vollborn e Vlad Georgescu. São autores de best-sellers, escritores de ciência e jornalistas de ciência desde 1994.Mais detalhes sobre a sua escrita em X-Press Journalistenbüro (https://xpress-journalisten.com).Mais informações na Wikipédia:Sobre Marita: https://de.wikipedia.org/wiki/Marita_Vollborn Sobre Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

Ver Biografia Completa

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

LabNews Media LLC

Mantenha-se Conectado

Reportagem inigualável

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

LabNews Media LLC

Artigos Semelhantes

40 graus: Onda de calor mortal atinge Portugal

Farinha de algas melhora bolachas sem glúten

Via imunitária específica de género descoberta no glioblastoma

Mantenha-se Conectado

Reportagem inigualável